Streetbeat News

Revenues

ISPR

Ispire Technology Inc. (NASDAQ: ISPR) has signed a 30-year exclusive global licensing agreement with Hidden Hills Club to manufacture, distribute, and commercialize Hidden Hills' nicotine products. The rollout will begin in the UAE and South Africa, followed by the UK and EU. This partnership aims to expand Ispire's product offerings and market reach, despite recent financial losses.

Portfolio Pulse from Rolando García

August 07, 2024 | 12:17 am

VREOF

Vireo Growth Inc. (OTC:VREOF) reported significant financial improvements for Q2 2024, including a $5.8M operating income compared to a $1M loss in Q2 2023. The company saw a 42.5% increase in revenue and a 45.2% rise in gross profit. SG&A expenses decreased by 6.1%, and the company secured a 30-month extension of its credit agreement.

Portfolio Pulse from Nicolás Jose Rodriguez

August 06, 2024 | 11:02 pm

OR

Osisko has revised its 2024 GEO delivery guidance to 77,000 – 83,000 GEOs, assuming that production at Eagle Mine will remain suspended through the end of 2024. The guidance also accounts for a two-month delay in Capstone's ramp-up at Mantos Blancos.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:13 pm

ITUB

Itau Unibanco Holding (NYSE:ITUB) reported Q2 2024 adjusted EPS of $0.20, beating the $0.19 estimate. Sales were $8.02 billion, surpassing the $7.70 billion estimate but down 1% from last year's $8.11 billion.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:09 pm

TMCI

Treace Medical Concepts has reaffirmed its FY24 revenue guidance of $201M - $211M, with an estimated $205.405M. The company also expects Adjusted EBITDA to improve by approximately 50% compared to full-year 2023.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:06 pm

PRCH

Porch Group has reaffirmed its revenue expectations for FY24, projecting between $450 million and $470 million, aligning closely with the estimated $457.544 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:01 pm

AQST

Aquestive Therapeutics has projected its FY24 revenue to be between $57 million and $60 million, surpassing the estimated $49.792 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:59 pm

MYO

Myomo projects Q3 revenue between $8M-$8.5M, slightly below the $8.35M estimate. FY revenue is expected to be $28M-$30M, close to the $28.66M estimate. The company aims for $10M in Q4 revenue and continued growth in 2025. Increased advertising spending in H2 2024 may impact cash flow breakeven.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:58 pm

REAL

The RealReal has updated its Q3 and FY24 revenue guidance. Q3 revenue is expected to be between $135M-$142M, below the $144.15M estimate. FY24 revenue is projected to be $580M-$595M, close to the $588.97M estimate. Adjusted EBITDA for Q3 is forecasted between $(2)M and $1M, and for FY24 between $0M and $6M.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:56 pm

NRC

National Research (NASDAQ:NRC) reported a decrease in Q2 GAAP EPS to $0.26 from $0.29 YoY and a decline in sales to $35.02M from $36.16M YoY.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:56 pm